EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Vabysmo (faricimab) by Roche Registration GmbH for treatment of wet age-related macular degeneration, macular edema, and diabetic macular ede…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications. MAH: Roche Registration GmbH. Decision date: 11/12/2025